Smith & Nephew shares dip on weak US knee implant sales

Smith & Nephew reported Q1 revenue of $1.50 billion, up 6.6% year over year and in line with the 3.2% underlying growth consensus, but Orthopaedics underperformed with just 0.8% underlying growth versus 2.5% expected due to a 10.3% decline in US knee implants. Sports Medicine & ENT beat expectations at 6.7% underlying growth, while management reiterated full-year 2026 guidance for around 6% underlying revenue growth, roughly $1.3 billion in trading profit, and about $800 million in free cash flow. The company also announced a new $500 million share buyback and a leadership change in Orthopaedics.

Analysis

The market is treating this as a clean “in-line plus buyback” quarter, but the more important signal is that management is explicitly sacrificing near-term knee volume to de-risk the launch ramp. That usually creates a temporary air pocket in reported growth, yet it can be accretive if the new system lands with surgeons and inventory conversion accelerates into Q3/Q4; the market is likely underpricing the leverage if LANDMARK meaningfully reclaims share from incumbent knee platforms.

The offsetting strength in Sports Medicine matters more than the headline miss because it suggests the company’s growth engine is shifting toward higher-quality, more durable procedure mix rather than volume-heavy ortho replacement cycles. If that mix shift persists, the multiple can expand even without dramatic top-line acceleration, since investors tend to pay up for recurring procedure growth and device pull-through versus “classic” implant replacement narratives.

The risk is that US knees remain weak longer than planned and the launch is judged against already-diluted baselines, creating a second-quarter sentiment gap before any benefit shows up. Reimbursement pressure in wound bioactives is a reminder that even within a stable guidance framework, payor mix can quietly compress the upside; that makes the next two quarters more about execution than the full-year target, and any slippage would hit the stock harder because buyback news may have already pulled forward some support.

The contrarian view is that the selloff may be too mechanical: a 1.9% move on a guided, capital-return-positive print implies the market is mostly focused on one underperforming subsegment while ignoring the probability that orthopedics can re-accelerate into the product cycle turn. The better setup is not a broad beta long, but a relative-value expression on execution versus expectations over the next 3-6 months.

Key Decisions for Investors

• Long SNN on pullbacks over the next 1-2 weeks, targeting a 3-6 month hold into the LANDMARK Knee System launch; risk/reward is attractive if the market is over-discounting temporary knee softness versus launch optionality.
• Pair trade: long SNN / short a slower-growth orthopedics peer with heavier US knee exposure for 1-2 quarters, betting that SNN’s product-cycle setup and buyback support outperform a more static implant mix.
• Sell downside via near-dated puts or put spreads into the next earnings window if implied volatility remains elevated; the thesis is that management has already framed the weakness, limiting further fundamental surprise unless launch timing slips.
• Add on confirmation if Sports Medicine growth stays high-single-digit or better over the next quarter; that would validate the mix shift and reduce dependence on knees, improving the stock’s medium-term multiple.
• Take profit into any post-launch strength if the market starts pricing the knee re-acceleration before actual share data is visible; the main risk is buying the rumor and missing the execution gap.